Aktis Oncology Q1 net loss widens to $18.3 million; collaboration revenue rises to $3.2 million
Aktis Oncology reported first-quarter 2026 results in an 8-K furnished with a press release. Collaboration revenue rose to $3.2 million from $1.4 million a year earlier, but the net loss widened to $18.3 million from $15.0 million as research and development and general and administrative expenses increased. Cash, cash equivalents and marketable securities reached $538.5 million at March 31, 2026, which the company says will fund operations into 2029.
Key points
- Collaboration revenue was $3.2 million for the quarter ended March 31, 2026, versus $1.4 million a year earlier, tied to the Eli Lilly research collaboration.
- Net loss was $18.3 million versus $15.0 million; R&D expenses rose to $20.0 million from $15.9 million and G&A expenses rose to $5.9 million from $3.7 million.
- Cash, cash equivalents and marketable securities were $538.5 million at March 31, 2026, up from $226.8 million at December 31, 2025, mainly due to net proceeds from the January 2026 initial public offering.
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.